Bailey Davis Lupo

Mr. Bailey Davis Lupo

orcid

Research Focus & Metrics

Academic Career Length

3Years (2024-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
Verified
Journal Article
Open access
PDF file
BLBailey Davis Lupo
Bailey Davis Lupo
WJWesley Jameson
Wesley Jameson
CQChristian Quinones
Christian Quinones
AMAlexandre Malek
Alexandre Malek
DKDeepak Kumbhare
Deepak Kumbhare
SHStanley Hoang
Stanley Hoang
Background/Objectives: Surgical site infections (SSIs) in spine surgery pose significant risks, including neurological deficits, prolonged hospital stays, and increased healthcare costs. SSIs are classified by their location and include superficial, deep, and organ/space (OS) infections. In spine surgery, OS SSIs include osteomyelitis, discitis, and spinal epidural abscess. These infections are difficult to treat with conservative measures, impart significant morbidity, and incur increasing hospital costs. Despite advancements in surgical technique and infection control, the literature is conflicting on which factors are associated with a significant increase in risk of SSIs after spinal surgery. There is also a significant gap in the literature in defining the risk factors specific to OS SSIs. This study aims to identify risk factors associated with SSI after spine surgery at a single institution, as well as provide descriptive characteristics of patients with OS SSIs. Methods: This retrospective study analyzed spinal surgeries performed at a multi-center, single-institution between 1 January 2019 and 9 February 2025. Neurosurgical patients who underwent spine surgery were identified by ICD-10 procedure and diagnosis codes. Surgical infections were classified based on the National Healthcare Safety Network (NHSN) criteria. Univariate and multivariate analyses were performed to assess associations between patient demographics, comorbidities, and infection risk. Results: Of the 2363 unique spinal surgery patients, 39 developed infections, with 14 meeting the NHSN criteria for OS SSI. The overall rate of SSIs at this institution was 1.65%. Significant risk factors for developing an SSI included cardiovascular disease (p = 0.017) and COPD (p = 0.012). Multivariate analysis confirmed both risk factors identified in the univariate analysis as independent risk factors, with adjusted odds ratios of 1.97 (p = 0.033) and 2.072 (p = 0.041), respectively. The commonly cultured pathogens included Staphylococcus aureus, Staphylococcus epidermidis, and methicillin-resistant Staphylococcus aureus. Conclusions: Male sex, diabetes mellitus, gastroesophageal reflux disease, hyperlipidemia, hypertension, hardware placement, and a history of smoking were more common in patients with SSI. In the OS SSI subgroup, cardiovascular disease and COPD were associated with an increased risk of developing an OS SSI. Future research is needed to investigate more detailed risk factors and include mitigating factors of OS infection into the analysis.

19 September 2024
Verified
Preprint
Open access
APAshtyn Phillippi
Ashtyn Phillippi
HDHayden Day
Hayden Day
BLBailey Davis Lupo
Bailey Davis Lupo
MJMatthew Johnson
Matthew Johnson
RKRoger Kelley
Roger Kelley
PLPatrick Luther
Patrick Luther
Neurodegenerative diseases like Alzheimer's, Parkinson's, Amyotrophic Lateral Sclerosis, and Huntington's share common underlying mechanisms driving progressive neuronal dysfunction and death. Key pathological features include protein aggregation, oxidative stress, mitochondrial dysfunction, and neuroinflammation. In Parkinson's disease, disruption of cellular homeostasis results from alpha-synuclein aggregation, whereas Amyotrophic Lateral Sclerosis is characterized by TDP-43 and superoxide dismutase 1 aggregates leading to motor neuron degeneration. Alzheimer's disease exhibits beta-amyloid plaques and hyperphosphorylated tau-related neurofibrillary tangles, impairing synaptic function and causing cognitive decline. Huntington's disease involves CAG repeat expansion in the HTT gene, causing mutant huntingtin protein aggregation and neuronal toxicity. Current therapeutic approaches provide symptomatic relief rather than targeting underlying disease mechanisms directly to potentially halt neuropathological progression or achieve neurorestoration. However, emerging therapies aim to intervene at these mechanistic levels. For example, in Parkinson's disease, treatments involving alpha-synuclein antibodies and small molecule inhibitors aim to mitigate protein aggregation. Amyotrophic Lateral Sclerosis therapies focus on reducing oxidative stress and inflammation, while Alzheimer's treatments aim to clear beta-amyloid plaques and tau tangles. Potential therapies for Huntington's disease include gene silencing and antisense oligonucleotides to reduce mutant huntingtin protein levels. Future directions include advancing personalized medicine approaches tailored to individual genetic and molecular profiles, alongside combination therapies targeting multiple pathological processes concurrently. Enhanced understanding of these shared mechanisms holds promise for developing effective disease-modifying treatments. Efforts towards neuroprotection and neurorestoration aim to not only alleviate symptoms but also slow or halt disease progression, offering hope for improved outcomes and quality of life for patients.

Verified
Journal Article
Open access
PDF file
WJWesley Jameson
Wesley Jameson
BLBailey Davis Lupo
Bailey Davis Lupo
ASAndrew Schwartz
Andrew Schwartz
ADAndrew W Daigle
Andrew W Daigle
AAAhmed Ibrahim Anwar
Ahmed Ibrahim Anwar
SHStanley Hoang
Stanley Hoang
Background/Objectives: Poor bone quality is strongly associated with adverse surgical events. Although dual-energy X-ray absorptiometry (DXA) remains the gold standard for bone mineral density (BMD) assessment, logistical barriers may limit its preoperative application. The Endplate Bone Quality (EBQ) score is an MRI-derived metric quantifying subchondral bone quality at the vertebral endplate with demonstrated predictive value for cage subsidence following lumbar interbody fusion. However, EBQ has been measured exclusively at the operative level in surgical cohorts. This study aimed to assess level-specific EBQ scores across the entire lumbar spine and compare distributions across age, sex and osteoporosis subgroups. Methods: A single-institution retrospective review of T1-weighted lumbar MRI studies from patients evaluated for lower back pain from 2020 to 2025 was performed. EBQ was independently scored by two blinded raters at each disc space from L1–L2 to L5–S1 using 3 mm endplate ROIs normalized to a CSF ROI at L3. Interrater reliability was assessed via ICC, Pearson correlation, and RMSE. Patients were stratified by age (≤60 vs. >60 years), sex, and osteoporosis status, and subgroup comparisons were performed for overall and level-specific EBQ score. Results: A total of 96 patients with an average age of 61.0 ± 9.42 years were included in this study. The majority of patients included were female (87.5%), and 18.8% had been diagnosed with osteoporosis. EBQ scores demonstrated a progressive caudal increase across all subgroups from L2–L3 to L5–S1. Overall interrater reliability was acceptable (ICC = 0.76), with level-specific ICCs ranging from 0.70 to 0.83. No significant differences were observed between age or sex subgroups. Osteoporotic patients demonstrated significantly higher EBQ at L1–L2, L2–L3, and overall (all p < 0.05), with no significant differences at L3–L4 through L5–S1. Conclusions: This study provides normative, level-specific EBQ reference data throughout all levels of the lumbar spine. The increase in EBQ scores seen among caudal levels and reduced osteoporotic discriminatory power support the importance of level-specific context when interpreting EBQ thresholds. These findings may support future studies evaluating threshold development for EBQ.